New York State Common Retirement Fund Chinook Therapeutics, Inc. Transaction History

New York State Common Retirement Fund

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$18.66 - $38.58 $202,013 - $417,667	-10,826 Reduced 18.53%	47,595 $1.83 Million
Q1 2023 May 02, 2023	SELL	$21.53 - $26.8 $251,793 - $313,426	-11,695 Reduced 16.68%	58,421 $1.35 Million
Q4 2022 Jan 30, 2023	BUY	$18.63 - $27.35 $134,899 - $198,041	7,241 Added 11.52%	70,116 $1.84 Million
Q3 2022 Nov 08, 2022	BUY	$17.51 - $23.37 $15,093 - $20,144	862 Added 1.39%	62,875 $1.24 Million
Q2 2022 Aug 04, 2022	BUY	$12.59 - $18.8 $397,403 - $593,422	31,565 Added 103.67%	62,013 $1.09 Million
Q1 2022 May 05, 2022	BUY	$12.02 - $16.69 $55,364 - $76,874	4,606 Added 17.82%	30,448 $498,000
Q4 2021 Feb 02, 2022	BUY	$10.69 - $16.83 $66,705 - $105,019	6,240 Added 31.83%	25,842 $421,000
Q3 2021 Nov 02, 2021	SELL	$11.5 - $14.86 $86,020 - $111,152	-7,480 Reduced 27.62%	19,602 $250,000
Q2 2021 Aug 02, 2021	BUY	$13.6 - $18.98 $208,120 - $290,450	15,303 Added 129.92%	27,082 $382,000
Q4 2020 Feb 08, 2021	BUY	$11.9 - $20.91 $140,170 - $246,298	11,779 New	11,779 $187,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.